Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low- and high-dose lorediplon significantly reduced mean Wake After Sleep Onset (WASO) throughout the night as measured by polysomnography vs. placebo (improvements of 19 and 23 minutes compared to placebo, respectively, p<0.0001 for both).

Lorediplon also met the secondary endpoint of improving WASO in the second half of the night vs. zolpidem. Lorediplon was well tolerated with dizziness, somnolence, headache, fatigue, hangover and nausea reported as the most common treatment-related adverse events...